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The resinous metabolites commonly known as frankincense or olibanum are produced by trees of the genus
Boswellia and have attracted increasing popularity in Western countries in the last decade for their various
pharmacological activities. This review described the pharmacological specific details mainly on anti-inflammatory,
anti-carcinogenic, anti-bacterial and apoptosis-regulating activities of individual triterpenoid together with the
relevant mechanism. In addition, species-characterizing triterpenic markers with the methods for their detection,
bioavailability, safety and other significant properties were reviewed for further research.
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The resins commonly known as frankincense or oliba-
num, which are obtained from trees of the genus
Boswellia, are the best-known of the aromatic gum
resins used throughout the world as incense in religious
ceremonies [1]. Moreover, frankincense has enormous
socio-economic importance. Historically, it has been
used as incense in religious and cultural ceremonies and
as an ingredient in traditional medicines since time im-
memorial, whereas currently, it is widely used as an ad-
hesives agent, as an ingredient in cosmetic preparations,
as a fragrance used in daily rituals, and as a coating for
materials. The medicinal properties of frankincense have
also been studied to shed light on its potential use in
treating or curing diseases [2,3]. The medicinal use of
frankincense may be among mankind’s oldest therapies
[4], and in the contemporary era, it is still used exten-
sively in regions ranging from North Africa to China.
Frankincense has been demonstrated to have curative
activity when used within the system of traditional medi-
cine called Ayurveda, which is practiced in India;* Correspondence: lv_cheng0816@163.com; yyliu_1980@163.com
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reproduction in any medium, provided the orhowever, it has fallen into obscurity during the present
era of synthetic drugs [5].
Much attention has been focused on the beneficial ef-
fects of frankincense as a medicinal component of therap-
ies targeting allergic asthma, inflammatory bowel diseases,
rheumatoid arthritis and osteoarthritis, brain tumors and
edema [6]. Meanwhile, it is also used in the treatment of
amenorrhea, menorrhagia, polyuria, scrofula, syphilis,
asthma, bronchitis, sores, and diseases of the nervous sys-
tem [7]. Generally speaking, frankincense is widely used as
an anti-inflammatory drug and numerous reports suggest
that triterpenoids may be the bioactive ingredients respon-
sible for these properties [6,8]. In addition, pure com-
pounds isolated from frankincense have anti-neoplastic
activity. Many studies have demonstrated the potent anti-
neoplastic activities of triterpenoids acids obtained from
frankincense, and especially boswellic acids (BAs) and
their derivatives. These compounds have been shown to
possess potential chemoprevention effects in prostate can-
cer [8,9], cervical cancer [10], breast cancer [11], colorectal
cancer [12], pancreatic cancer [13] and bladder cancer
[14]. In light of what is known of the medicinal properties
of these metabolites, the present review places special em-
phasis on the pharmacological activities of the characteristic
components of frankincense, such as acetyl- 11-keto-β-
boswellic acid (AK-β-BA) (4). Aside from the naturalal Ltd. This is an Open Access article distributed under the terms of the Creative
commons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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pounds that have been shown to possess conspicuous
pharmacological activities following modification of their
structures (48–53) as these may provide new leads for
future pharmaceutical research aimed at developing and
synthesizing novel analogs with desired characteristics.
Given the diverse pharmacological activities of the
compounds present in frankincense, it is important to
characterize the pharmacological activities of frankin-
cense harvested from different species and to identify
species-specific differences in activity and therapeutic
potential. On the basis of published studies, we review
the triterpenoid resinous metabolites that are present in
frankincense obtained from several different Boswellia
species with respect to their medicinal properties. In our
review of triterpenoid activities, structures and species-
specific profiles, we have attempted to include all of the
triterpenoids from frankincense that have been studied
to date. To draw distinctions between the resins from
various species of Boswellia in terms of their medicinal
potential, the pharmacological activities and the primary
mechanisms of action of the characteristic triterpenoids
are discussed as far as possible.
Identification of Boswellia species
Various sources
Frankincense exudes from incisions in the bark of trees of
the Boswellia (Burseraceae) genus and approximately 25
species belonging to this genus are used sources of this
resin. These species are widely distributed in India, Arabia
and the northeastern coast of Africa. As has been reported
previously, the trees referred to as “true frankincense-
producing trees” may in fact be any of several main
Boswellia species depending on the geographical location
in question [4,15-17], and these species are listed below.
♦ Boswellia sacra Flueck. (found in Southern Arabia) is
known in Arabia as “maghrayt d’sheehaz”, and the resin
it produces is known as “lubãn dhakar”.
♦ Boswellia carterii Birdw. (found in Somalia and
Southern Arabia) is better known as “Mohr”. This
specie is also found in Sudan and, in rare cases, in
Yemen. Boswellia bhau-dajiana Birdw. (found in
Somalia), whose local name is “Mohr-add”, has recently
been found to be identical to B. carterii. Generally, the
resins that both species produce are called “lobãn
dakar” or are more commonly referred to as “beeyo”
quality.
♦ Boswellia frereana Birdw. (found in Somalia)
produces the most expensive type of olibanum on the
market, and this resin is known as “lobãn majdi” or,
more commonly, as “maydi”.
♦ Boswellia papyrifera Hochst. (found in East Africa),
another deciduous, gum-producing, multipurposeperennial tree that grows in Somalia, Ethiopia, Eritrea,
Sudan and in the other east African countries, is
claimed to have been the source of olibanum in
antiquity and produces resin of a quality known as
“boido” [4,7,18].
♦ Boswellia serrata Roxb. (found in East India) is also
known as “Indian olibanum” and is found in the central
and northern parts of east India [3]. This specie
produces olibanum resins of various qualities, which
are commonly known as “salai guggul”.
In spite of the diversity in the species from which
frankincense is obtained and their broad and often over-
lapping geographical ranges, the gum-producing trees
are generally referred to as follows: B. papyrifera (“Afri-
can frankincense”), B. frereana (“African frankincense”),
B. serrata (“Indian Frankincense”) and B. carterii/B. sacra
(“Arabian frankincense”) [19-21]. However, it should be
noted that there are divergent opinions concerning B.
carterii that have led to some researchers referring to
this specie as “African frankincense” [21].
The quality and the commercial value of resins differ
based on the species from which they are obtained. In
general, the finest and most expensive frankincense is
maydi from B. frereana, while the most common is
beeyo from B. carterii or Boswellia bhau-dajiana Birdw
[22]. Thus, the identification of species-specific marker
profiles would be a significant advance that could pro-
vide a rapid way to distinguish the different types and
sources of frankincense, and this could be used in a
commercial context to appraise resins.
The characteristic triterpenic compounds of Boswellia
species
As detailed above, the triterpenic compounds have been
shown to have potential as markers that can identify the
source of frankincense. Below is a summary of the char-
acteristic triterpenic compounds of various Boswellia
species.
♦ B. carterii and B. sacra olibanum have quite similar
chemical compositions and are characterized by the
presence of lupeolic acid (25), BAs and their respective
O-acetyl derivatives [23,24].
♦ B. serrata is characterized by the presence of
tirucallane [25] and euphane [26] skeletons, which are
not commonly found in Boswellia species, in addition
to BAs and their respective O-acetyl derivatives.
♦ B. frereana is characterized by the presence of lupeol
(29) and 3-epi-lupeol (28) [23,27] in conjunction with
triterpenes with dammarane [28] skeletons. Lupeolic
acid (25), BAs (1, 15) and their respective O-derivatives
(26, 2 and 16) are not found in frankincense from these
species [23].
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cense from the various Boswellia species are summa-
rized in Table 1. The natural resinous triterpenoids can
be grouped into the following 6 types: ursane-type
triterpenes (type U), oleanane-type triterpenes (type O),
lupane-type triterpenes (type L) and tirucallane-type
triterpenes (type T), dammarane-type triterpenes (type
D) and euphane-type triterpenes (type E). Their corre-
sponding structures are shown in Figure 1 and Figure 2.
Type U, type O and type L belong to the pentacyclic
triterpenes class, while type T, type D and type E are
classified as tetracyclic triterpenes. Compounds 1–15
and 48–52 are of type U and are divided into three sub-
classes based on the number of double bonds attached
to the aromatic nucleus. Compounds 1–12 and 48–52,
all possess one double bond at C-12 and a subset of
these also have a carbonyl group at C-11. Compounds
13 and 14 have two double bonds located at C-9 (11)
and C-12 (13), respectively, and do not have a carbonyl
group, while compounds 15 are saturated. Compounds
16–24 and 53 are of type O and the skeletons of them
possess one or two double bonds attached to the aro-
matic nucleus. Compounds 35–42 which belong to the
type T are divided into three sections in the light of the
number and the positions of double bonds in aromatic
nucleus. Moreover, compounds 25–34, 43–46 and 47 are
classified as type L, type D and type E respectively.
Species-characterizing triterpenic markers and methods
The ability to identify the source of frankincense may
lead to improvements in the quality of the products pro-
duced using this resin. A rapid means of identifying the
source of frankincense on the basis of characteristic
markers of each species is necessary to achieve this end.
Such an identification method will also be very useful in
efforts to characterize the presence of resins from differ-
ent species in archaeological samples. In early studies,
attention was focused on the diterpenes and volatiles,
which have been regarded as the primary diagnostic
markers in generic assays, and the methods used
consisted of GC, GC-MS, pyrolysis-GC-MS, solid phase
micro extraction and thin layer chromatography (TLC).
However, other published studies provide evidence of
the utility of the triterpenoid resinous metabolites as
species-specific markers [22,23]. The primary methods
used to detect these markers are TLC and high perform-
ance liquid chromatography (HPLC).
Differentiating B. frereana-produced resins from B. carterii
and B. sacra-produced resins
A reversed-phase high performance liquid chromato-
graphic procedure (RP-HPLC) has been developed that
is aimed at differentiating between resins obtained from
different species [23]. Testing of this method usingresins with known botanical origins [17] demonstrated
that it was not able to reliably distinguish B. carterii
resin from that of B. sacra because the resins of these
two species have similar chemical compositions that re-
sult in qualitatively similar chromatograms. Neverthe-
less, this chromatographic method is able to distinguish
the finest and most expensive Somalian olibanum resin
produced by B. frereana from the other common Arabian
and African resins produced by B. sacra and B. carterii. In
fact, B. frereana resin produced a characteristic chromato-
graphic profile in which 3-epi-lupeol (28) was the most
prominent peak, while lupeolic acid (25), boswellic acids
(1, 15) and their respective O-derivatives (26, 2 and 16)
were not detected [23]. The absence of these latter
compounds is surprising because they have been found
to be the major components in frankincense resins an-
alyzed previously. In summary, B. carterii and B. sacra
resins are characterized by the presence of lupeolic
acid (25), BAs and their respective O-acetyl derivatives,
whereas 3-epi-lupeol (28) in methanolic extracts can
be considered to be a marker that is characteristic of B.
frereana resins. Thus, these findings form the basis of
a simple method for differentiating resins produced
by B. carterii or B. sacra from those produced by B.
frereana. Moreover, this method could be used in a
commercial context to distinguish common olibanum
(beeyo) from the finest and the most expensive frank-
incense (maydi) [23].
Differentiating B. papyrifera-produced resins from B.
carterii and B. sacra-produced resins
A normal phase TLC method has been developed which
is able to distinguish between resins produced by
B. carterii or B. sacra and those obtained from B.
papyrifera. An eluent consisting of a mixture of pentane
and diethyl ether (2:1) with 1% acetic acid is used in
conjunction with anisaldehyde dyeing reagent in this
method, and the resulting chromatograms are analyzed
by UV detection (254 nm) [19]. In tests of this method,
it was possible to distinguish significant differences be-
tween the three olibanum species after the dyeing,
heating and color development steps. B. papyrifera
shows a strong blue spot at Rf = 0.22 which corresponds
to 3-oxo-8, 24-dien-tirucallic acid (elemonic acid) (36),
while B. carterii and B. sacra samples lack this spot. This
is consistent with the results of HPLC analysis in which
B. carterii and B. sacra show smaller peak areas for this
compound than are found in data from B. papyrifera
samples. Moreover, when these spot areas are slowly
heated after dyeing, the spot corresponding to elemonic
acid undergoes a characteristic series of color changes in
which it first becomes a greenish spot, and then turns to
blue after approximately 24 h before finally turning to
brown [19]. This is a useful means of confirming the
Table 1 Characteristic triterpenoids in frankincense harvested from various Boswellia species
Type No. Common name Systematic name Resource Ref.
Pentacyclic triterpenes
U 1 β-Boswellic acid (β-BA) 3α-hydroxy-urs-12-en-24-oic acid B .carterii, B. sacra, B. serrata [18,29,30]
2 3-acetyl-β-BA (Aβ-BA) 3α-O-acetyl-urs-12-en-24-oic acid B. serrate, B .carterii [5,29]
3 11-keto-β-BA (Kβ-BA) 3α-hydroxy-11-oxo-urs-12-en-24-oic acid B. carterii, B. serrata [29,31]
4 3-acetyl-11-keto-β-BA (AKβ-BA) 3α-O-acetyl-11-oxo-urs-12-en-24-oic acid B. carterii, B. serrata [31,32]
5 12-ursene-2-diketone urs-12-en-3,11- diketone B. serrata [33]
6 3-acetyl-11α-methoxy-β –BA 3α-O-acetyl-11α-methoxy-urs-12-en-24-oic acid B. carterii [34]
7 \ 2α,3α-dihydroxy-urs-12-en-24-oic acid B. serrata. [35]
8 urs-12-en-3α,24-diol 3α, 24-dihydroxyurs-12-ene B. serrata. [35,36]
9 α-amyrenone urs-12-en-3-one B. carterii, B. serrata [27,37]
10 3-epi-α-amyrin 3α-urs −12-en-3-ol B. carterii, B. serrata [27]
11 α-amyrin 3β-urs-12-en-3-ol B. carterii, B. serrata [27,38]
12 3-acetyl-11-hydroxy-BA 3α-O-acetyl-11-hydroxy-urs-12-en-24-oic acid B. serrata [39]
13 3-acetyl-9,11-dehydro-β-BA 3α-O-acetyl-9,11-dehydro-urs-12-en-24-oic acid B. carterii [31]
14 9,11-dehydro-β-BA 3α-hydroxy-9,11-dehydro-urs-12-en-24-oic acid B. carterii [31]
15 18Hα,3β,20β-ursanediol 3, 20β-dihydroxy-urs-3-ol B. carterii [40]
*48 11-keto-diol 3α,24-dihydroxy-11-oxo-urs-12-ene * [41]
*49 11-keto-β-BA methyl ester 3α-11-oxo-urs-12-en-24-oic acid methyl ester * [41]
*50 acetyl-11-keto-amyrin 3β-acetyl-11-oxo-urs-12-ene * [41]
*51 hexanoyloxy-11-keto-β-BA (HKBA) 3α-O-n-hexanoyl-11-oxo-urs-12-en-24-oic acid * [42]
*52 butyryloxy-11-keto-β-BA (BKBA) 3α-O-n-butyryl-11-oxo-urs-12-en-24-oic acid * [42,43]
O 16 α-Boswellic acid (α-BA) 3α-hydroxy-olean-12-en-24-oic acid B. carterii, B. serrata [18]
17 3-acetyl α-BA(Aα-BA) 3α-O-acetyl-olean-12-en-24-oic acid B. serrate, B. carterii [29,44]
18 β-amyrenone olean-12-en-3-one B. carterii, B. serrata [18]
19 3-epi-β-amyrin 3α-olean-12-en-3-ol B. carterii, B. serrata [18]
20 β-amyrin 3β-olean-12-en-3-ol B. carterii, B. serrata [18,45]
21 \ 3α,24-dihydroxy-olean-12-ene B. serrata [10,36]
22 olibanumol E 3α-hydroxy-11-methoxyl-olean-12-ene B. carterii [46]
23 9,11-dehydro-α-BA 3α-hydroxy-9,11-dehydro-olean-12-en-24-oic acid B. serrata [47]
24 3-acetyl-9,11-dehydro-α-BA 3α-O-acetyl-9,11-dehydro-olean-12-en-24-oic acid B. serrata [44]
*53 3-acetyl-11-keto-α-BA 3α-O-acetyl-11-oxo-olean-12-en-24-oic acid * [48]
L 25 lupeolic acid 3α-hydroxy-lup-20(29)-en-24-oic acid B. carterii [21]
26 acetyl-lupeolic acid 3α-O-acetyl-lup-20(29)-en-24-oic acid B. carterii [21]
27 lupenone lup-20(29)-en-3-one B. frereana [18]
28 epi- lupeol 3α-lup-20(29)-en-3-ol B. frereana [18]
29 lupeol 3β-lup-20(29)-en-3-ol B. frereana, B. carterii [18,29]
30 3-acetyl-28-hydroxy-lupeolic acid 3α-O-acetyl-28-hydroxy-lup-20(29)-en-24-oic acid B. carterii [49]
31 3-acetyl-27-hydroxy-lupeolic acid 3α-O-acetyl-27-hydroxy-lup-20(29)-en-24-oic acid B. papyrifera [7]
32 methyl-3α-O-acetyl-27-hydroxy-lupeolic acid 3α-O-acetyl-27-hydroxy-lup-20(29)-en-24-oate B. papyrifera [7]
33 olibanumol F 3α-lup-20(29)-en-3- acid ester B. carterii [46]
34 olibanumol G 3α,5α-dihydroxy-lup-20(29)-en-24-oic acid B. carterii [46]
Tetracyclic triterpenes
T 35 α-elemolic acid 3α-hydroxy-tir-8,24-dien-21-oic acid B. carterii, B. serrata [25,50]
36 elemonic acid (3-oxo-tirucallic acid) 3-oxo-tir-8,24-dien-21-oic acid B. carterii, B. serrata [9,25,29]
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Table 1 Characteristic triterpenoids in frankincense harvested from various Boswellia species (Continued)
37 β-elemolic acid 3β-hydroxy-tir-8,24-dien-21-oic acid B. carterii, B. serrata [25,29,50]
38 3β-acetoxy-tireucallic acid 3β-O-acetyl-tir-8,24-dien-21-oic acid B. carterii [9]
39 3α-acetoxy-tirucallic acid(B) 3α-O-acetyl-tir-8,24-dien-21-oic acid B. serrata [25,51]
40 \ 3α-hydroxy-tir-7,24-dien-21-oic acid B. carterii [50]
41 3α-acetoxy-tirucallic acid(A) 3α-O-acetyl-tir-7,24-dien-21-oic acid B. carterii [9,50]
42 \ 3-oxo-tir-7,9(11),24-trien-21-oic acid B. carterii [40]
D 43 \ 3β-O-acetyl-16(S),20(R)-dihydroxy-dammar-24-ene B. frereana [28,52]
44 \ 3β,20(S)-dihydroxy-dammar-24-ene B. frereana [28]
45 \ 3β-O-acetyl-20(S)-hydroxy-dammar-24-ene B. frereana [28]
46 20(S)-protopanaxadiol 3β-hydroxy-12β,20(S)-dihydroxy-dammar-24-ene B. frereana [28]
E 47 \ 20,22-epoxyeupha-24-ene-3-one B. serrata [26]
* Artificially synthesis.
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elemonic acid (36) as a characteristic marker in TLC-
based assays to differentiate B. papyrifera resins from
those obtained from B. carterii or B. sacra.
Tests of this TLC method led to two other important
observations: (i) B. papyrifera samples have the strongest
AKβ-BA (4) spot, while in B. serrata and B. carterii/B.
sacra samples the AKβ-BA (4) spots are weaker and
have approximately equal absorbance, and (ii) without
the use of UV detection, Kβ-BA (3) is clearly detectable
only in B. papyrifera and B. serrata resin samples,
whereas in those from B. carterii and B. sacra the spot
can only be detected by UV at this concentration level
[19]. To some extent, these differences may also be help-
ful in distinguishing B. papyrifera resins from those of
other species and will encourage future research to es-
tablish a more effective method of identifying resins
from Boswellia species.
Differentiating “Indian frankincense” from “African
frankincense”
A HPLC gradient method [21] has been used to identify
the compounds present in “Indian frankincense” and
“African frankincense” collected from the B. serrata spe-
cies and the B. carterii and B. frerean species, respect-
ively. The results showed a significant difference in the
ratio of AKβ-BA (4) to Kβ-BA (3). In these resins, AKβ-
BA (4) was found to be the predominant compound in
African frankincense, while twice as much Kβ-BA (3)
was found in Indian frankincense. The ratio of these
compounds (4:3) is approximately 0.7 and 4.7 in Indian
and African frankincense, respectively [21]. Furthermore,
the results indicated that the total amount of pentacyclic
triterpenic acids present was approximately 25% lower in
Indian frankincense than in African frankincense, but this
finding must be regarded with reservation. All in all, “In-
dian frankincense” (B. serrata) and “African frankincense”(B. carterii and B. frereana) could be approximately differ-
entiated by this HPLC method on the basis of differences
in the ratio of AKβ-BA (4) to Kβ-BA (3).
Pharmacological activities
In view of both the medicinal importance of triterpenoids
in the treatment of various chronic diseases and evidence
[53,54] suggesting that both natural and synthetic triter-
penoids have potential pharmacological activities, our
review has so far only scratched the surface of this very
fertile field of investigation and has concentrated on the
noteworthy triterpenoids. In terms of the pentacyclic
triterpenoids, for instance, BAs, lupeolic acids and their
derivatives are common compounds with diverse pharma-
cological activities, including antifungal, antimicrobial,
antioxidant [55] and antitumor activities [56]. Similarly,
the tetracyclic triterpenoid resinous metabolites also have
pharmacological activities. For example, tirucallic acids and
their acetoxy- derivatives have been demonstrated to po-
tently inhibit cell proliferation and to induce apoptosis in
tumors [9]. Moreover, some compounds (48–53) synthe-
sized from BAs [41-43,48], the characteristic components
of frankincense, also show distinct bioactivity and will be
introduced in detail (Additional file 1).
On the basis of many studies, the triterpenoid resinous
metabolites from the genus Boswellia have been shown
to exhibit various pharmacological activities in vitro and
in vivo against various health-related conditions, includ-
ing inflammation, microbial infection and cancer. These
pharmacological activities are summarized below, to-
gether with the mechanism of action of the triterpenoids
(shown in Figure 3).
Anti-inflammatory activity
Inflammation is a complex process involving numerous
mediators with cellular and plasma origins, and these
mediators have elaborate, interrelated biological effects
Figure 1 Structures of triterpenoids 1–34, 48–53.
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resinous metabolites are largely ascribed to the inhib-
ition of 5-lipoxygenase (5-LOX), nitric oxide synthase
(iNOS), cyclooxygenase-2 (COX-2) and nuclear factor-
κB (NF-κB) activities. COX-2 and 5-LOX, two enzymes
involved in the oxygenation of arachidonic acid, are
upregulated in the central nervous system during aging
and are associated with various aging-related brain
pathologies [58]. Additionally, excessive and prolonged
iNOS-mediated nitric oxide (NO) generation has been
linked to both inflammation and tumorigenesis [59].
For clearer understanding of the inflammatory patho-
genesis and relevant pro-inflammatory cytokines, its
complicated is diagramed in Figure 3 and described in
detail below.
Production of eicosanoid compounds, specifically leu-
kotrienes, prostaglandins and lipoxin, is induced by ara-
chidonic acid in the metabolism. Eicosanoids are potent
lipid mediators of inflammation that are derived from
phospholipase-released arachidonic acid through subse-
quent metabolism by (COX)-1/2 [60] or LOX and areinvolved in a variety of homeostatic biological functions
and inflammation. With the liberation of arachidonic
acid in the cell, several enzymatic reactions take place
involving different types of enzymes, such as 12-LOX,
5-LOX, 15-LOX and COX, and each reaction leads to
the production of a different type of inflammation me-
diator. BAs were found to be specific, non-reducing-
type inhibitors of the 5-LOX activity that act either by
interacting directly with the 5-LOX or by blocking its
translocation [31]. Therefore, suppression of leukotri-
ene synthesis via inhibition of 5-LOX is considered to
be the main mechanism underlying the anti-inflammatory
effect of BAs [61].
COX, also referred to prostaglandins endoperoxide
synthase, is a membrane protein which catalyzes the
conversion of arachidonic acid and O2 to prostaglandins
endoperoxide H2, the committed step in prostanoid bio-
synthesis [62]. Two COX isoforms, COX-1 and COX-2,
which are encoded by distinct genes, have been de-
scribed in mammalian cells. Both isoforms are interest-
ing in the context of both their structural biology and
Figure 2 Structures of triterpenoids 35–47.
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containing, glycosylated proteins with two catalytic sites
[62]. These two isozymes are also important pharmaco-
logically as targets of aspirin and other nonsteroidal
anti-inflammatory drugs (NSAIDs). COX-2 may be espe-
cially important as an NSAID target mediating the in-
hibition of colon cancer. Although COX-2 is thought to
be involved primarily in the inflammatory response, it is
also likely to be involved in many essential physiological
functions because disruption of the COX-2 gene in mice
results in renal dysplasia, cardiac fibrosis, and defects in
the ovary [63]. Reports [64,65] have also shown that
blockade of COX-1 activity results in multiple severe
side effects, such as bleeding in the intestinal tract and
impairment of renal function. It is therefore of key im-
portance to note that many studies have demonstrated
that certain BAs and their derivatives potently inhibit
COX-2 and can also show selective activity against
COX-1 [66,67].
Nitric oxide (NO) is an important biological mediator
that is synthesized from L-arginine by two isoforms of
nitric oxide synthase (NOS), namely constitutive nitric
oxide synthase (cNOS) and inducible nitric oxide syn-
thase (iNOS) [57]. At physiological concentrations, NO
inhibits proinflammatory platelet aggregation, integrin-
mediated adhesion, and proinflammatory-induced geneexpression, and these are factors that control vascular
inflammation and oxidative injury. However, the over-
production of NO that is catalyzed by iNOS, a soluble
enzyme that is active in its dimeric form, is cytotoxic
[68]. Immunostimulating cytokines and bacterial patho-
gens activate iNOS and generate high concentrations of
NO through the activation of inducible nuclear factors,
including NF-κB [68]. Overall, the overproduction of
NO by iNOS is important in inflammation and its re-
lated processes, and high levels of NO are markers for
the diagnosis of inflammatory disorders. Targeting NF-
κB is considered important in inhibiting NOS because it
is the main regulatory step in the pathway leading to
iNOS expression.
NF-κB (nuclear factor kappa-light-chain-enhancer of
activated B cells) is a protein complex that controls the
transcription of DNA. Activation of the NF-κB is initi-
ated by the signal-induced degradation of IκB proteins
[69]. Signal-induced activation of IκB kinase leads to the
phosphorylation and degradation of IκB, liberating NF-
κB from the IκB inhibitory proteins [70]. With the
degradation of IκB, the NF-κB complex is then freed
to enter the nucleus where it can ‘turn on’ the expres-
sion of specific genes that have DNA-binding sites for
NF-κB nearby [53]. After activation of IκB-NF-κB com-
plex, free NF-κB transfers into the nucleus and induces
Figure 3 Some triterpenoids exhibit their anti-inflammatory activity by inhibiting LPS-stimulated COX-2 and iNOS expression in
macrophages by limiting the translocation of NF-κB protein into the nucleus. Signal-induced activation of IκB kinase leads to the
phosphorylation and degradation of IκB, liberating NF-κB from the IκB inhibitory proteins. With the degradation of IκB, the NF-κB complex is then
freed to enter the nucleus where it can ‘turn on’ the expression of specific genes that have DNA-binding sites for NF-κB nearby and induces the
expression of iNOS and the release of proinflammatory such as MIF, IL-6, IL-1, TNF-α. TNF-α is triggering either pro-inflammatory effects via NF-κB
related pathways or apoptosis through activation of caspase-8 and triterpenoids induce apoptosis by modulating different caspases and their
cleavage. TNF binds its receptor TNF-α and can activate the pro-inflammatory and anti-apoptotic NF-κB pathway via activation of the IKK
complex. Moreover, TNF can induce the pro-apoptotic caspase–cascade via adaptor proteins TRADD and FADD and proteolytic activation of
procaspase-8. Activated caspase-8 in turn cleaves and thus activates effector caspases such as caspase-3 and induces the apoptosis eventually.
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proinflammatory such as MIF, IL-6, IL-1, TNF-α [71]
and NO by molecules [53,72] (showed in Figure 3).
Again, it is important to note that multiple studies have
found that subsets of the resinous triterpenoids are able
to suppress NF-κB activation, and we discuss this in
more detail below.
Type U triterpenoid anti-inflammatory activities
The type U triterpenoids β-BA (1) and Aβ-BA (2) inhibit
12-O-tetradecanoylphorbol-13-acetate (TPA)-induced in-
flammation in mice [50]. Beta-BA (1) can also inhibit the
effects of lipopolysaccharide (LPS) through direct molecu-
lar interference [73] and has been shown to be a selective
inhibitor of COX-1 with IC50 values of approximately
15 μM [66]. In addition, β-BA (1) enhances the release
of arachidonic acid via cytosolic phospholipase A2 activ-
ity, and platelet-type 12-LOX catalysis has been found
to increase by approximately 2-fold in its absence, whereas
AKβ-BA (4) inhibited platelet-type 12-LOX activity which
was identified as a selective molecular target [74]. A form
of β-BA (1) lacking β-keto function has been found to me-
diate only partial inhibition of 5-LOX. Studies [75,76] have
revealed that the carboxyl group and the 11-keto group
of AKβ-BA (4) in combination are essential for enzyme
inhibition, while the acetoxy group at position C-3α in-
creases the affinity of AKβ-BA (4) for the effector site.Moreover, hydrophilic group on C-4 of ring A with the
pentacyclic triterpene ring is crucial for binding to the
enzyme and for the 5-LOX activity. Furthermore, these
reports demonstrated that minor structural modifica-
tions could cause a total loss of the binding affinity
and/or the inhibitory activity of these compounds. As
was reproted that the saponification of AKβ-BA’s 3α-
acetoxy-group slightly decreased the activity of (3) (IC50 =
3 μM), whereas the substitution with longer aliphatic,
lipophilic side chains (e. g. (52), an esterification with
butyrylic acid) did not alter the 5-lipoxygenase inhibitory
activity [75].
Kβ-BA (3) and AKβ-BA (4) both showed marked anti-
inflammatory activity against TPA-induced in mice with
a 50% inhibitory dose (ID50) of 0.07 and 0.08 (mg/ear)
[50]. Additionally, AKβ-BA (4) proved to have significant
effects in inhibiting 5-LOX and human leukocyte elastase
[8,77] and promoted down-regulating of the expression
of COX-2, matrix metalloproteinase-9, C-X-C chemokine
receptor 4, and vascular endothelial growth factor in vivo
[13]. AKβ-BA (4) has also been shown to enhance the
release of arachidonic acid via cytosolic phospholipase
A2 [74] and has been reported to be a selective inhibitor
of COX-1 [66].
12-ursene 2-diketone (5) isolated from B. serrata was
analyzed for inhibitory effects on key inflammatory me-
diators, such as TNF-α, IL-1β and IL-6 and the results
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inflammatory cytokines and mediators via inhibition of
phosphorylation of the mitogen activated protein ki-
nases, c-jun N-terminal kinase and p38 [33]. However,
no inhibition of extracellular signal-related kinase phos-
phorylation was observed in LPS-stimulated peripheral
blood mononuclear cells [33].
3-acetyl-11α-methoxy-β–BA (6) also shows inhibitory
activity against TPA-induced inflammation in mice [50].
α-amyrin (11) and β-amyrin (19) have similar physio-
logical activities in that they affect COX-2 product
synthesis slightly [67], while they exhibit pronounced
anti-inflammatory effects and suppress the levels of
inflammatory cytokines and COX-2 levels. This may
occur via inhibition of NF-κB activity and of signaling
pathways involving phospho-cyclic AMP response element-
binding protein [78]. Coincidently, 3-acetyl-9, 11-dehydro-
β-BA (13) and 9, 11-dehydro-β-BA (14) also share similar
activity profiles in that both compounds inhibit TPA-
induced inflammation in mice [50].
Type O triterpenoid anti-inflammatory activities
Alpha-BA (16) and Aα-BA (17) show similar inhibitory
activity against TPA-induced inflammation in mice [50]
and selectively inhibit COX-1 [66]. β-amyrenone (18)
and 3-epi-β-amyrin (19) show antifungal and cytotoxic
activities in the same range as the organic crude extract
and have low-level toxic effects on mononuclear cells
obtained from human peripheral blood [79]. Further-
more, olibanumol E (22) inhibits NO production in
LPS-activated mouse peritoneal macrophages [80] and
also shows inhibitory activity against TPA-induced in-
flammation in mice [50]. The only artificially synthesized
compound belonging to type O was assayed for physio-
logical activity and was found to inhibit the 5-LOX [41].
Type L triterpenoid anti-inflammatory activities
The type L compounds lupeolic acid (25) and acetyl-
lupeolic acid (26), both show inhibitory activity against
TPA-induced inflammation in mice [50]. It has been
reported that lupenone (27) inhibits protein tyrosine
phosphatase 1B [81]. Epi-lupeol (28), which was identi-
fied as the principal constituent of B. frereana-derived
resins, prevents collagen degradation and inhibits the
production of pro-inflammatory mediators and matrix
metalloproteinase [82]. Lupeol (29) is a multi-target agent
with immense anti-inflammatory potential targeting key
molecular pathways which involve NF-κB, cFLIP, Fas,
Kras, phosphatidylinositol-3-kinase (PI3 κ)/Aκt and
Wnt/β-catenin in a variety of cells and its effective
therapeutic doses exhibit no toxicity to normal cells and
tissues [83]. It has been reported to inhibit NF-κB signal-
ing, including the phosphorylation of the IκB-α protein,
and inhibits the binding of the NF-κB complex to DNA,thereby inhibiting NF-κB-dependent reporter gene activity
[84-86]. Finally, 3-acetyl-28-hydroxy-lupeolic acid (30) can
inhibit the biosynthesis of COX-, 5-LO- and 12-LO-de-
rived eicosanoids from endogenous arachidonic acid in ac-
tivated platelets, neutrophils, and monocytes from human
blood [49].
Type T triterpenoid anti-inflammatory activities
Alpha-elemolic acid (35), elemonic acid (3-oxo tirucallic
acid) (36), 3α-hydroxy-tir-7, 24-dien-21-oic acid (40) and
3α-acetoxy-tirucallic acid (A) (41) show inhibitory activ-
ity against 12-O-tetradecanoyl phorbol-13-acetate-in-
duced inflammation in mice [50].
Anti-carcinogenic or anti-tumor activities
Resinous triterpenoids, including the BAs, have been
suggested to have anti-neoplastic activity as a result of
their anti-proliferative and pro-apoptotic properties.
The cytochrome P450 (CYP) superfamily of enzymes
plays a central role in the metabolism of carcinogens
and anti-cancer drugs [87]. Enhanced expression of CYP
in a variety of human cancers suggests that CYP may be
a new tumor marker protein, and it has been reported to
be an important factor in resistance to anti-cancer drugs
[88]. CYP is, therefore, a new and valuable target for
anti-cancer strategies.
Epstein–Barr virus, a human herpesvirus, establishes a
persistent asymptomatic infection of the circulating B
lymphocyte pool [89]. Moreover, it can enhance the car-
cinogenic effects of viral and chemical carcinogens. The
triterpenoids from resins have been studied with regard
to their inhibitory effects on TPA-induced Epstein–Barr
virus early antigen (EBV-EA) activation and, thus, as po-
tential antitumor agents.
The transcription factor nuclear factor-kappa B (NF-κB)
and inhibitor of NF-κB kinase (IKK) proteins are impli-
cated in various cellular processes, including innate- and
adaptive-immune responses, cell death and inflammation
[69]. However, aberrant and sustained NF-κB or IKK ac-
tivity has been implicated in various stages of tumorigen-
esis and is found in a number of cancers [69,90]. NF-κB is
activated by Akt and mitogen-activated protein kinase
p38, and the expression of these proteins can be decreased
to inhibit NF-κB signaling [91].
In addition to interventions in the pathways listed above,
topoisomerase IIα, the key enzyme in DNA replication is a
molecular target for many anti-cancer drugs called topoII
inhibitors [92]. Moreover, modulation of the expression of
the let-7 and miR-200 microRNA families [93] and others
are also fundamental anti-tumor approaches.
Type U triterpenoid anti-tumor activities
Beta-BA (1) and Kβ-BA (3) has been reported to possess
anti-carcinogenic properties by virtue of its ability to
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values in the range of 5 μ and 10 μM [94]. It also has
moderate inhibitory effects on EBV-EA activation (IC50
431–499 mol ratio/32 pmol TPA). [34]. Moreover, Aβ-
BA (2) is cytotoxic for the human glioma cell lines U87
MG and U373 MG [95] and this acetyl-BA derivative in-
teracts with human topoisomerases through high-affinity
binding sites yielding KD values of 70.6 nM for topo-
isomerase I and 7.6 nM for topoisomeraseIIα [95]. In
the orthotopic nude mouse model of pancreatic cancer,
p.o. administration of AKBA alone (100 mg/kg) signifi-
cantly inhibited the tumor growth [13]. Moreover, it
shows inhibitory effects on EBV-EA induction [34].
AKβ-BA (4), belongs to the type U class of pentacyclic
triterpenes and has considerable anti-tumor activity.
Firstly, this compound can induce increased expression
of the CCAAT/enhancer binding protein homologous
protein and DR 5 [8]. Secondly, it inhibits the prolifera-
tion of four different pancreatic cancer cell lines (AsPC-
1, PANC-28, MIA pancreatic cancer-2 with K-Ras and
p53 mutations, and BxPC-3 with wild-type K-Ras and
mutated p53) [13]. Thirdly, it induces a decrease in Ki-
67 expression, a biomarker of proliferation, and of
CD31, a biomarker of microvessel density in tumor tis-
sue [13]. AKβ-BA (4) has also been reported to inhibit
human topoisomerases I and IIα [8,95] and may also
suppress NF-κB activation [12]. In addition, it proved
cytotoxic for the human glioma cell lines U87 MG and
U373 MG [95] and all of the three human neuroblast-
oma cells lines IMR-32, NB-39, and SK-N-SH [34]. Fi-
nally, the compound has potent inhibitory effects on
applied CYP enzymes with IC50 values in the range of
5 μ and 10 μM [94] and exerts antitumor effects on
colorectal cancer cells by modulating the expression of
the let-7 and miR-200 microRNA families [96]. It has
been reported that 3-acetyl-11α-methoxy-β–BA (6) showed
similar activity to that of cisplatin against NB-39 and
had inhibitory effects on EBV-EA activation [34]. As for
the artificially synthesized compound HKBA (51), this
can inhibit the enzymatic activity of topoisomerases I and
II at 20 μg/ml [42]. In contrast, the BKBA (52) compound
functions by inhibiting the NF-κB and STAT proteins,
which act both as signal transducers and as activators of
transcription, and this compound may therefore be devel-
oped into a potential anti-cancer therapeutic agent in the
future [43].
Type O triterpenoid anti-tumor activities
Aside from the aforementioned type U compounds, the
triterpenediol (TPD) compounds 3α, 24-dihydroxyurs-
12-ene (8) and 3α, 24-dihydroxyolean-12-ene (21), which
belong to the type O class, are both able to induce up-
regulation of the cell death receptor 4 (DR 4) and TNF-α1,
and thereby promote caspase-8 activation and produceoxidative stress in cancer cells [36]. In turn, these changes
trigger cell death via activation of both the intrinsic and
extrinsic signaling cascades that are regulated by reactive
oxygen species and NO. Conversely, these compounds
also induce a decrease in the expression of components of
the PI3K/pAkt, ERK1/2, and NF-kB/Akt signaling cas-
cades which coordinately contribute to cancer cell survival
[10]. The final type O terpenoid we will discuss, AKα-BA
(53), exhibits anti-cancer activity and has been shown
to inhibit the growth of chemotherapy-resistant human
PC-3 prostate cancer cells in vitro and to induce apop-
tosis by activation of caspase 3 and induction of DNA
fragmentation [48].
Type L triterpenoid anti-tumor activities
Lupane triterpenoids are of a particular interest from a
medicinal perspective, and their biological activities have
attracted attention since the 19th century. For instance,
lupeolic acid (25) shows potent inhibitory effects on
EBV-EA induction [34]. Lupeol (29) has therapeutic ef-
fects in some cancers, in addition to its inhibitory effects
on NF-κB signaling described above it seems that it has
the potential to inhibit several other signaling pathways,
such as the Akt-dependent pathways, and this may en-
hance its anti-cancer properties [86]. Lupeol (29) has
been reported to have a potent inhibitory effect on hu-
man leukocytic elastase [97] and was also shown to sup-
press the growth of HL-60 human leukemia cells by
inducing apoptosis [98]. It has also been shown to sup-
press the malignization of murine melanoma, and it
achieves this not only by inhibiting cell proliferation but
also by a direct cytotoxic effect [99]. This triterpenoid
also has anti-tumor effects on NSGLG-N6 human large
cell bronchopulmonary carcinoma [100].
Type T triterpenoid anti-tumor activities
Elemonic acid (3-oxo-tirucallic acid) (36), β-elemolic acid
(37), 3α-hydroxy-tir-7, 24-dien-21-oic acid (40) and 3α-
acetoxy-tirucallic acid (A) (41) can show potent inhibitory
effects on EBV-EA induction [34]. Furthermore, elemonic
acid (3-oxo tirucallic acid) (36) and the acetoxy-derivatives,
3β-acetoxy-tireucallic acid (38) and 3α-acetoxy-tirucallic
acid (A) (41) in particular potently inhibited the activities of
human recombinant Akt1 and Akt2 and of constitutively
active Akt immunoprecipitated from PC-3 cells [9].
Apoptosis-regulating activities
Apoptosis, or cell suicide, is a form of cell death that is
morphologically and biochemically distinct from necro-
sis [101]. Previous studies have indicated that apoptosis
provides a critical regulatory mechanism in inflamma-
tory processes [101] and cancer. Caspase activation plays
a central role in the execution of apoptosis and one of
the key components of the biochemical pathways of
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pathway. In this pathway, activation of caspase-8 follow-
ing its recruitment to the death-inducing signaling com-
plex is the critical event that transmits the death signal.
Activated caspase-8 can activate downstream caspases
by direct cleavage or can act indirectly by cleaving Bid
and inducing cytochrome c activity. Activated caspase-9
then cleaves and activates downstream caspases, such as
caspase-3, -6, and −7 [102,103]. Reports [36,104,105]
have shown that some of the resinous triterpenoids in-
duce apoptosis in cancer cells and leukemia cell lines by
caspase activation. Besides, the pleiotropic cytokine
tumor necrosis factor (TNF) alpha is triggering either
pro-inflammatory effects via NF-κB related pathways or
apoptosis through activation of caspase-8 [103] (the
pathway is showed in Figure 3). TNF binds its receptor
TNF-α and can activate the pro-inflammatory and
anti-apoptotic NF-κB pathway via activation of the IKK
complex. Active IKK complexes phosphorylate IκBα
resulting in its ubiquitination and thus release and nu-
clear translocation of NF-κB subunits p50 and p65, where
this transcription factor activates pro-inflammatory and
anti-apoptotic genes. Moreover, TNF can induce the pro-
apoptotic caspase–cascade via adaptor proteins TRADD
and FADD and proteolytic activation of procaspase-8.
Activated caspase-8 in turn cleaves and thus activates
effector caspases such as caspase-3 and induces the
apoptosis eventurally [103] (showed in Figure 3).
It is reported that AKβ-BA (4) induces apoptosis
through a cells DR 5-mediated pathway in prostate can-
cer and it activates caspase-8 and caspase-3 in both
LNCaP and PC-3 cells [8]. Kβ-BA (3) and AKβ-BA (4)
increased caspase-8, caspase-9 and caspase-3 activities
accompanied by cleavage of PARP [61]. Moreover, Aα-
BA (17) and Akβ-BA (4) convey inhibition of NF-κB and
subsequent down-regulation of TNF-α expression in ac-
tivated human monocytes via their direct inhibitory ef-
fects on IKK [106,107].
Other activities of triterpenoid resinous metabolites
The triterpenoids from the genus Boswellia have several
physiological activities aside from those already discussed.
These have been the subject of fewer reports, and we will
therefore consider them one-by-one instead of grouping
them by type.
Beta-BA (1) exhibited anti-microbial activity against
112 pathogenic bacterial isolates including American
Type Culture Collection strains [108]. AKβ-BA(4) was
found to be an active compound showing an minimal in-
hibitory concentration (MIC) range of 2–8 μg/ml against
the entire gram positive bacterial pathogens tested. It
exhibited concentration-dependent killing of Staphylo-
coccus aureus ATCC 29213 at up to 8 times MIC, and a
post-antibiotic effect of 4.8 h at 2 ×MIC [108]. It canalso act as an antibacterial agent by inhibiting the forma-
tion of biofilms generated by S. aureus, S.mutans, Acti-
nomyces and Staphylococcus epidermidis and by
reducing preformed biofilms generated by these bacteria
[108,109].
Kβ-BA (3), AKβ-BA (4), 3-acetyl-27-hydroxy-lupeolic
acid (31), methyl-3α-O-acetyl-27-hydroxy-lupeolic acid
(32) and β-Elemolic acid (37) show inhibitory activity
against prolyl endopeptidase [7]. Beta-BA(1) can increase
the length distribution of microtubule proteins and can
also increase the polymerization rate of tubulin, thereby
moderately stabilizing it and diminishing both the crit-
ical concentration and the fraction of inactive tubulin
[110]. Anti-elastase activity has also been reported in the
literature [111]. Alpha-amyrenone (9) is a compound
that stands out in terms of its activity because of its in-
hibitory effects on a purified HIV-1 reverse transcriptase
[112]. Finally, lupenone (27) inhibits protein tyrosine
phosphatase 1B [81], while 3α-acetoxy-tirucallic acid (B)
(39) can initiate MEK-1/2 phosphorylation [51]. More-
over a study showed that the mixtures of BAs derive
from B. carterii have immunomodulatory properties by
inhibiting TH1 cytokines and promoting TH2 cytokines
in vitro [113].Safety
In comparison to NSAIDs, which one-third of patients
suffer from gastric or duodenal ulcers when taking per-
manently, the resinous metabolites from Boswellia spe-
cies have attracted increasing popularity in Western
countries in the last decade [6]. Several pilot clinical tri-
als suggest promising beneficial therapeutic effects with
no serious, long-term, or irreversible adverse effects
[114] but some minor adverse effects such as diarrhoea,
abdominal pain and nausea [115,116]. A study deals with
the evaluation and assessment of the safety/toxic poten-
tial of B. serrata indicated that B. serrata is relatively
safe in rat up to the dose of 500 mg/kg B.wt [117]. An-
other safety profile of alcoholic extract of stem-bark of
B. ovalifoliolata was investigated and proved the safety
with no observed adverse effect level is 500 mg/kg fol-
lowing repeated oral administration for 28 days in rats
[118]. In addition, the efficacy, safety and tolerability
of B. serrata extract was compared with valdecoxib in
66 patients of osteoarthritis of knee for six months,
which showed that B. serrata extract was superior to
valdecoxib in these aspects and only few patients
complained of acidity. diarrhea or abdominal cramps
[119]. Although the observed adverse effects in further
clinical trials with greater numbers of patients is neces-
sary, the previous insights suggested BAs from Boswellia
to be well tolerated with fewer adverse effects as com-
pared with NSAIDs.
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On accounts of their potent anti-inflammatory and anti-
tumor action as we showed, triterpenoid resinous me-
tabolites from the genus Boswellia represent a potential
remedy for the complementary treatment of various dis-
eases. However, a major limitation is the low systemic
absorption in rodents and humans of BAs, especially of
the major active compounds (1–4) (16–17), which have
been evidenced by pharmacokinetic studies [120,121].
For example, the plasma and brain concentrations of
BAs were found to be very low following oral adminis-
tration of even high B. serrata doses [114]. In general,
AKβ-BA (4) was not detected at all [38] while β-BA (1)
and Aβ-BA (2) achieved pharmacologically relevant con-
centrations in plasma [114]. Besides, a permeability
study on the intestinal absorption revealed poor perme-
ability (<1 × 10−6 cm/s) of AKβ-BA (4) [120] and moder-
ate absorption of Kβ-BA (3) with a Papp value of 1.69 ×
10−6 cm/s in the Caco-2 model [122].
Although the sparing solubility of BAs in water and the
highly lipophilic (log P = 7-10.3) [123], they can be select-
ively extracted by using alkyl benzene sulfonate solutions
[124]. The hydrotropes cooperatively form microassemblies
in aqueous solutions which, in turn, are responsible for
the solubilization of water-insoluble organic substances
owing to their amphiphilic structures [124]. The solubility
of BAs was increased by 2 orders of magnitude in the
presence of hydrotropes in aqueous solutions and the
efficiency of the extraction depends on the hydropho-
bic nature of the hydrotrope and also increases with its
concentration [124].
To bring the efficacy of triterpenoid resinous metabo-
lites into full play, melioration is necessary by overcom-
ing the limitation of the poor bioavailability. For better
prediction of the absorption in vivo, the permeability ex-
periments should be more adapted to physiological con-
ditions of the gastrointestinal tract by the addition of 4%
bovine serum albumin to the receiver side [120,125],
and using modified fasted state simulated intestinal fluid
as apical (donor) medium [114]. Under these conditions
the four BAs lacking the 11-keto moiety (β-BA (1), Aβ-
BA (2), Kβ-BA (3) and AKβ-BA (4)) showed moderate
permeability with Papp-values between 1 and 10 × 10
−6
cm/s [120], suggesting moderate absorption (20–70%)
according to Yee [126]. Furthermore, the permeability of
Kβ-BA (3) and AKβ-BA (4) was improved compared to
earlier studies from 2.14 × 10−6 cm/s to 29.54 × 10−6 cm/s
for Kβ-BA (3) and from <1 × 10−6 cm/s to 17.83 × 10−6
cm/s for AKβ-BA (4) [120].
Moreover, a formulation composed of extract/phospho-
lipid/pluronic f127 (1:1:1 w/w/w) increased the solubility
of (1–4) (16–17) up to 54 times compared with the
nonformulated extract and exhibited the highest mass
net flux in the permeability tests [114]. The oraladministration of this formulation to rats (240 mg/kg)
resulted in 26 and 14 times higher plasma levels for
Kβ-BA (3) and AKβ-BA (4), respectively [114]. In the
brain, five times higher levels for AKβ-BA (4) com-
pared to the nonformulated extract were determined 8
h after oral administration [114]. Another experiment
[120] indicated the availability of all six major BAs (1–4)
(16–17) could be confirmed in rat brain 8 h after oral ad-
ministration of 240 mg/kg gum resin extracts to rats show
mean concentrations of 1066.6 ng/g for β-BA (1), 163.7
ng/g for Aβ-BA (2), 11.6 ng/g for Kβ-BA (3), 37.5 ng/g for
AKβ-BA (4), 485.1 ng/g for α-BA (16) and 43.0 ng/g for
Aα-BA (17). In addition, lecithin formulation significantly
improves the absorption of BAs and promotes their tissue
penetration [121].
Review and conclusions
This review summarized a total of 53 compounds and 47
components that have been reported to be among the tri-
terpenoid resinous metabolites from the genus Boswellia,
and discusses what is known of their physiological activ-
ities from more than one hundred published studies.
We noted that the triterpenoid resinous metabolites
pharmacological activities consisting of anti-inflammatory,
anti-carcinogenic, anti-bacterial and apoptosis-regulating
activities. Triterpenoid resinous metabolites especially BAs
have generated an extensive interest due to the various
beneficial pharmacological properties. Besides their po-
tent anti-inflammatory effects, triterpenoids have shown
promising activities against multiple malignancies [8-13].
Also, we discussed various mechanisms by which triter-
penoids regulate various transcription and growth factors,
inflammatory cytokines [127], and intracellular signaling
pathways involved in cancer cell apoptosis [53]. They
inhibit the production of numerous cytokines [127], indu-
cible enzymes [58,94], and induce apoptosis in tumor cell
lines [13,95,104]. Therefore, it has significant potential to
serve as a novel agent for cancer prevention and therapy.
Among the important chemoprevention and therapeutic
target pathways are NF-κB [53], STAT3 [43] and MAP
[33]. The extracts of the gum-resin of Boswellia carteri,
Boswellia frereana, Boswellia sacra and Boswellia serrata
are identified as equally potent, non-selective inhibitors of
the major drug metabolising CYP enzymes [94] and as a
selective COX-2 inhibitor [119]. In addition, BAs potently
suppressed the proteolytic activity of human cathepsin G
(IC50 of approximately 600 nM) in a competitive and
reversible manner [38].
Several pilot clinical trials suggest promising beneficial
therapeutic effects with no serious, long-term, or irre-
versible adverse effects but some minor adverse effects.
This suggested BAs of Boswellia to be well tolerated
with fewer adverse effects as compared with NSAIDs.
Major active compounds (boswellic acids), however, have
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tinal absorption. This limitation has been addressed by
developing a new formulations composed of extract/
phospholipid/pluronic f127 (1:1:1 w/w/w) [114].
As we have seen, the triterpenoid resinous metabolites
in Boswellia have extensive distributions and the phyto-
chemical investigations conducted to date mainly focus
on 5 Boswellia species, namely B. carterii, B. serrata, B.
sacra, B. papyrifera and B. frereana. The characteristic
triterpenoids of these species have potential identifying
properties that may be used in efforts to accurately iden-
tify the species origins of frankincense. In focusing on
the nature and utility of these triterpenoid profiles, our
suggested approach offers an alternative to the method
of identification used in previous studies, which uses
diterpenes and volatiles as the main identifying markers.
On the basis of the experimental evidence, which
shows the potential of triterpenoid resinous metabolites
as agents for the prevention and treatment of cancer in
addition to various diseases associated with inflamma-
tion, future studies should be focused on conducting
detailed, preclinical studies of triterpenoid toxicity, bio-
availability, pharmacodynamics and biomarkers and on
extensive evaluation of tumor inhibition using adenocar-
cinoma as an efficacy end point, before undertaking ex-
tensive clinical trials [53]. In addition, existing studies
support the assertion that structural modifications of
triterpenoids is likely to provide greater bioavailability
and efficacy in clinical applications. Above all, more re-
search is needed to clearly identify all of the potential
applications of the various species of resinous metabo-
lites that can be isolated from the genus Boswellia.
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